Active, not recruitingPHASE1, PHASE2NCT04639050

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

Studying Early-onset autosomal dominant Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hoffmann-La Roche
Principal Investigator
Clinical Trials
Hoffmann-La Roche
Intervention
RO7126209(drug)
Enrollment
241 target
Eligibility
50-85 years · All sexes
Timeline
20212030

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04639050 on ClinicalTrials.gov

Other trials for Early-onset autosomal dominant Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for Early-onset autosomal dominant Alzheimer disease

← Back to all trials